Pharmafile Logo
Pharmafocus logo
Advanced Search

Tysabri

Showing 8 posts of 8 posts found.

biogen_idec_hillerod_2008

Biogen halts Tysabri trial after failure in acute ischemic stroke

February 8, 2018
Research and Development Biogen, Tysabri, multiple sclerosis, pharma, stroke, trial failure

Biogen has halted its investigation into the efficacy of its humanised monoclonal antibody Tysabri (natalizumab) in the treatment of acute …

News
biogen_idec_hillerod_2008

Biogen says European regulatory committee adopts positive view for Tysabri

June 1, 2016
Medical Communications, Research and Development, Sales and Marketing Biogen, CHMP, EMA, Tysabri, multiple sclerosis

Biogen (Nasdaq: BIIB) said the European regulatory committee has backed the approval of a variation to the marketing authorization for its …

News
Elan image

Perrigo pays $8.6 billion for Elan

July 30, 2013
Research and Development, Sales and Marketing Elan, Perrigo, Tysabri

Generics firm Perrigo has snapped up Ireland-based Elan in a multi-billion dollar deal, ending a bitter takeover battle that has …

News
elan image

Elan sceptical of Royalty

February 26, 2013
Sales and Marketing Elan, FDA, Tysabri, royalty pharma

Elan Corporation has poured tepid water on private equity firm Royalty Pharma’s putative offer this week for the Irish biotech …

News
Genzyme

Genzyme MS drug approved in US

September 13, 2012
Medical Communications Aubagio, Genzyme, Rebif, Sanofi, Tysabri, gilenya, multiple sclerosis

US regulators have given the green light for Genzyme’s Aubagio to treat patients with relapsing forms of multiple sclerosis (MS). …

News
Tsyabri image

Elan to spin off drug discovery arm

August 14, 2012
Research and Development, Sales and Marketing Elan, Neotype Biosciences, Tysabri, multiple sclerosis

Elan Corporation is to spin off its drug discovery arm Neotype Biosciences to create a separate, quoted company by the …

News

In brief: European Medicines Agency news

January 26, 2010
Research and Development, Sales and Marketing Arepanrix, Arzerra, EMEA, GSK, Tysabri

GlaxoSmithKline’s influenza vaccine Arepanrix has been granted conditional marketing authorisation in Europe under an emergency fast-track procedure.It is the fourth …

News

European regulators begin Tysabri review

October 26, 2009
Sales and Marketing EU, Tysabri, reg

European regulators have begun a risk-benefit review of Biogen Idec’s multiple sclerosis drug Tysabri, which has been linked to 23 …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026